Secondary Neoplasm

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and var… (full text at CIViC)

PMID 7977367 · Whaley et al., 1994 · Open in CIViC

In a study of 31 kidney tumor from France, 14 somatic VHL mutations were found. Most tumors were found to have heterozygous pattern of mutation likely due to contamination of renal cancer tissues with… (full text at CIViC)

PMID 7591282 · Bailly et al., 1995 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and var… (full text at CIViC)

PMID 7977367 · Whaley et al., 1994 · Open in CIViC

A single case (70 year-old named "3GT" in this study) with sporadic grade 3 renal cell carcinoma was observed with both W8* and G44D somatic variants.

PMID 11536052 · Ma et al., 2001 · Open in CIViC

This study analyzed tumor and non-tumor kidney tissue from 195 unrelated patients with sporadic clear cell renal cell carcinoma (CCRCC) for a relationship between VHL variants in sporadic CCRCC and 'g… (full text at CIViC)

PMID 11505222 · Gallou et al., 2001 · Open in CIViC

Tissue analysis from 61 VHL patients, 30 sporadic renal cell carcinoma (RCC) tumor samples, and 6 sporadic RCC cell lines revealed 22 variants within VHL patients, 10 variants in tumor samples and var… (full text at CIViC)

PMID 7977367 · Whaley et al., 1994 · Open in CIViC

This variant was detected in a single case with clear-cell renal cell carcinoma. The tumor had two somatic variants (c.1-1_20del21 and c.291_310del20). Either of these variants is predicted to be quit… (full text at CIViC)

PMID 15932632 · van Houwelingen et al., 2005 · Open in CIViC

Bakouny, et al. (2022) performed a comprehensive study of the molecular and clinical features of 90 translocation renal cell carcinomas (tRCCs), defined as subtype of kidney cancer driven by MiT/TFE g… (full text at CIViC)

PMID 34986355 · Bakouny et al., 2022 · Open in CIViC

In this 2023 study, the authors evaluated the diagnostic utility of NR4A3 immunohistochemistry in acinic cell carcinoma (AciCC) of the salivary gland. The cohort included 128 AciCCs, comprising 85 cla… (full text at CIViC)

PMID 36469101 · Klubíčková et al., 2023 · Open in CIViC

In this 2019 study, the authors aimed to evaluate the usefulness of NR4A3 immunostaining and compare it with NR4A3 Fluorescence in situ hybridization (FISH) for the differential diagnosis of acinic ce… (full text at CIViC)

PMID 31094928 · Haller et al., 2019 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

In patients with KRAS wild-type (KRASwt) tumors druggable gene fusions have been identified. These alterations included recurrent NRG1 rearrangements predicted to drive PDAC development through aberra… (full text at CIViC)

PMID 29802158 · Heining et al., 2018 · Open in CIViC

Two patients were found to harbor gene fusions maintaining the kinase domain of NTRK1 (3' partner), specifically: MPRIP-NTRK1 and CD74-NTRK1. Both of these fusions lead to constitutive kinase activit… (full text at CIViC)

PMID 24162815 · Vaishnavi et al., 2013 · Open in CIViC

RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with … (full text at CIViC)

PMID 27825636 · Drilon et al., 2016 · Open in CIViC

In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC)

Open in CIViC

Study describes a 31-year old male, never-smoker patient with advanced NSCLC. Testing did not indicate tumor had EGFR mutation or ALK rearrangement. First line erlotininb did not yield a response. Aft… (full text at CIViC)

PMID 22215748 · Bergethon et al., 2012 · Open in CIViC

A tissue microarray of 268 patients with histologically confirmed colorectal adenocarcinoma was performed to search for ROS1 gene fusion events to guide potential targeted therapy in future cases. Bre… (full text at CIViC)

PMID 24296758 · Aisner et al., 2014 · Open in CIViC

This study screened 983 Renal Cell Carcinoma (RCC) cases and identified 65 tumors with morphologic features suspicious of RCC with Xp11.2 translocation/TFE3 gene fusion (Xp11.2 RCC). TFE3 immunohistoc… (full text at CIViC)

PMID 26169997 · He et al., 2015 · Open in CIViC

Argani. et al,. (2016) included a total of 60 cases with known TFE3 gene rearrangements in this study of Xp11 translocation positive neoplasms (47 RCC, 8 PEComa, and 5 melanotic renal cancers). The ag… (full text at CIViC)

PMID 26975036 · Argani et al., 2016 · Open in CIViC

Bakouny, et al. (2022) performed a comprehensive study of the molecular and clinical features of translocation renal cell carcinomas (tRCCs), defined as subtype of kidney cancer driven by MiT/TFE gene… (full text at CIViC)

PMID 34986355 · Bakouny et al., 2022 · Open in CIViC

Renal cell carcinomas (RCCs) with t(6;11)(p21;q12) are extremely rare and are characterized by a specific chromosome translocation involving the transcription factor EB (TFEB). Identification of eithe… (full text at CIViC)

PMID 22895266 · Rao et al., 2012 · Open in CIViC

Within a preclinical study the inhibitory effects of AZD1775 in esophageal squamous cell carcinoma (ESCC) was demonstrated in both in vitro and in-vivo samples that predominantly displayed high expres… (full text at CIViC)

PMID 31427973 · Bi et al., 2019 · Open in CIViC

In this study, the sensitivity to Cisplatin (a platinum-based drug) was studied in XRCC3 knockout, and ORC1 mutant PDX models. A role of XRCC3 loss in cisplatin sensitivity was reported in the study. … (full text at CIViC)

PMID 37029129 · Ter Brugge et al., 2023 · Open in CIViC

In preclinical small cell lung carcinoma (SCLC) models with YES1 amplification or high expression, treatment with the YES1 inhibitor CH6953755 (30 mg/kg, q2d) or dasatinib (45 mg/kg daily) produced ma… (full text at CIViC)

PMID 35988891 · Redin et al., 2022 · Open in CIViC

Efficacy of second-line sorafenib treatment (initially 12.5 mg/day, escalated to 25 mg/day) in a 82-year old male patient with type 2 papillary renal cell carcinoma was confirmed with a partial respon… (full text at CIViC)

PMID 32743370 · Morinaga et al., 2019 · Open in CIViC